TABLE 3.

Multivariable regression analyses of risk factors for achievement of breast pCR and nodal pCR

Characteristic	Odds Ratio	95% Confidence Interval	P
Breast pCR
Clinical T stage  1  2  3  4	(ref) 0.87 0.56 1.04	– 0.54–1.40 0.31–0.99 0.51–2.09	– 0.6 0.05 > 0.9
Histology  Invasive ductal  Classic lobular  Non-classic lobular	(ref) 0.09 0.98	– 0.01–0.46 0.36–2.37	– 0.02 > 0.9
Receptor status  ER+/HER2-  ER+/HER2+  ER-/HER2+  ER-/HER2-	(ref) 3.43 14.5 3.20	– 2.09–5.74 8.49–25.5 1.96–5.36	– < 0.001 < 0.001 < 0.001
Lymphovascular invasion  No  Yes	– 0.51	– 0.35–0.75	– < 0.001
Nodal pCR
Clinical N stage  0  1  2  3	(ref) 0.09 0.13 0.10	– 0.04–0.18 0.04–0.43 0.03–0.29	– < 0.001 0.001 < 0.001
Histology  Invasive ductal  Classic lobular  Non-classic lobular	(ref) 0.80 4.25	– 0.27–2.33 1.33–12.9	– 0.7 0.01
Receptor status  ER+/HER2-  ER+/HER2+  ER-/HER2+  ER-/HER2-	(ref) 2.79 5.42 1.89	– 1.49–5.33 2.19–14.0 1.02–3.50	– 0.002 < 0.001 0.04
Achievement of breast pCR (ypT0)	14.6	6.84–33.7	< 0.001

Abbreviations: pCR, pathologic complete response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2